市場調査レポート
商品コード
1308235
心臓POC検査装置市場:製品タイプ、エンドユーザー、地域別、2023-2028年Cardiac PoC Testing Devices Market by Product Type (Cardiac Markers Test, Analyzers), End User (Hospitals, Diagnostic Laboratories, and Others), and Region 2023-2028 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
心臓POC検査装置市場:製品タイプ、エンドユーザー、地域別、2023-2028年 |
出版日: 2023年07月05日
発行: IMARC
ページ情報: 英文 147 Pages
納期: 2~3営業日
|
世界の心臓POC検査装置市場規模は、2022年に17億5,000万米ドルに達しました。今後、IMARC Groupは、2023年から2028年にかけて6.10%の成長率(CAGR)を示し、2028年までに24億7,000万米ドルに達すると予測しています。タバコの過剰摂取による心血管疾患の有病率の増加、脳性ナトリウム利尿ペプチド、キナーゼ、トロポニン合成、乳酸脱水素酵素アイソザイムの検出ニーズの高まり、医療業界の繁栄などが市場を牽引する主な要因です。
心臓ポイントオブケア(POC)検査装置は、心臓疾患の迅速かつ正確な診断のために設計された革新的でポータブルな医療機器です。コンパクトで使いやすく、リアルタイムの結果が得られるため、医師は患者のケアについて迅速かつ十分な情報に基づいた決定を下すことができます。医療従事者が患者のベッドサイドで診断検査を実施する能力を提供し、検査室ベースの検査の必要性を排除し、重要な心臓評価のターンアラウンドタイムを短縮します。正確で信頼性の高い結果を数分以内に提供することで、臨床ワークフローの効率を高めます。心臓バイオマーカー分析、凝固モニタリング、コレステロール・プロファイリング、電解質測定など、さまざまな診断検査の実施を支援します。検査結果を即座に得ることができるため、患者のトリアージを効率化し、救急部の混雑を緩和し、資源配分を最適化することができます。集中型検査室への依存を減らすことで、サンプルの輸送、検査室の人員、インフラに関連するコストを最小限に抑えることができるため、心臓POC検査装置の需要は世界中で高まっています。
現在、タバコやアルコールの過剰摂取による心血管疾患の有病率の上昇は、市場の成長を後押しする重要な要因の1つです。さらに、世界中で心筋梗塞や冠症候群を検出するための心臓POC検査装置の利用が増加しています。これは、医療業界の繁栄とともに、市場の成長を支えています。さらに、脳性ナトリウム利尿ペプチド、キナーゼ、合成トロポニン、心不全時に生成される乳酸脱水素酵素アイソザイムを同定するために、これらのデバイスの採用が増加していることが、市場にプラスの影響を与えています。このほか、主要企業は、心血管疾患に対するスマートフォン・ベースの検査の立ち上げに注力しています。また、技術的に高度な心臓バイオマーカー分析装置の開発も進んでおり、これが市場の成長を後押ししています。さらに、検査に内在する膜のばらつきを考慮した内部標準を提供するソフトウェアや、ユーザーの利便性と視覚的な明瞭さのための統合LCDディスプレイを備えているため、心臓分析装置に対する需要が増加しています。また、全血、血清、血漿中のバイオマーカー濃度を定量化できるため、臨床診断にも役立ちます。さらに、POC検査装置の技術的進歩が進んでいることも、市場の見通しを良好なものにしています。
The global cardiac PoC testing devices market size reached US$ 1.75 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 2.47 Billion by 2028, exhibiting a growth rate (CAGR) of 6.10% during 2023-2028. The growing prevalence of cardiovascular diseases due to excessive consumption of tobacco; rising need to detect brain natriuretic peptides, kinase, synthesizing troponin, and lactate dehydrogenase isoenzymes; and the thriving medical industry represent some of the key factors driving the market.
Cardiac point-of-care (PoC) testing devices are innovative and portable medical instruments designed for the rapid and accurate diagnosis of cardiac conditions. They are compact, user-friendly, and offer real-time results, enabling physicians to make prompt and informed decisions about patient care. They provide healthcare professionals with the ability to conduct diagnostic tests at the bedside of patients, eliminate the need for laboratory-based testing, and reduce turnaround times for critical cardiac assessments. They enhance the efficiency of clinical workflows by delivering accurate and reliable results within minutes. They assist in performing a variety of diagnostic tests, including cardiac biomarker analysis, coagulation monitoring, cholesterol profiling, and electrolyte measurement. They aid in obtaining immediate test results that facilitate more efficient patient triage, reduce overcrowding in emergency departments, and optimize resource allocation. As they minimize costs associated with sample transportation, lab personnel, and infrastructure by reducing the reliance on centralized laboratories, the demand for cardiac PoC testing devices is rising worldwide.
At present, the rising prevalence of cardiovascular diseases due to the excessive consumption of tobacco and alcohol represents one of the crucial factors bolstering the growth of the market. Moreover, there is an increase in the utilization of cardiac PoC testing devices to detect myocardial infarction and coronary syndromes around the world. This, along with the thriving medical industry, is supporting the growth of the market. In addition, the growing employment of these devices to identify brain natriuretic peptides, kinase, synthesizing troponin, and lactate dehydrogenase isoenzymes that are generated during heart failure is positively influencing the market. Besides this, key players are focusing on launching smartphone-based tests for cardiovascular diseases. They are also developing technologically advanced cardiac biomarker analyzers, which is bolstering the growth of the market. Additionally, there is a rise in the demand for cardiac analyzers, as they have software to provide an internal standard to account for membrane variability that is intrinsic to tests and integrated LCD displays for user convenience and visual clarity. This, coupled with the ability of analyzers to quantify the concentration of biomarkers in whole blood, serum, and plasma, which helps in clinical diagnosis, is impelling the growth of the market. Furthermore, the growing technological advancements in PoC testing devices are offering a favorable market outlook.
IMARC Group provides an analysis of the key trends in each segment of the global cardiac PoC testing devices market, along with forecasts at the global, regional, and country levels from 2023-2028. Our report has categorized the market based on product type and end user.
Cardiac Markers Test
Cardiac Troponin (cTn) Test
Myoglobin Test
Creatine Kinase MB Isoenzyme (CK-MB) Test
Combinational Test Kits
Brain Natriuretic Peptide (BNP) Test
Analyzers
The report has provided a detailed breakup and analysis of the cardiac PoC testing devices market based on the product type. This includes cardiac markers test [cardiac troponin (cTn) test, myoglobin test, creatine kinase MB isoenzyme (CK-MB) test, combinational test kits, and brain natriuretic peptide (BNP) test] and analyzers. According to the report, analyzers represented the largest segment.
Hospitals
Diagnostic Laboratories
Others
A detailed breakup and analysis of the cardiac PoC testing devices market based on the end user has also been provided in the report. This includes hospitals, diagnostic laboratories, and others. According to the report, diagnostic laboratories accounted for the largest market share.
North America
United States
Canada
Asia Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa
The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America was the largest market for cardiac PoC testing devices. Some of the factors driving the North America cardiac PoC testing devices market included the growing cardiovascular burden among the population, increasing healthcare expenditure, rising geriatric population, etc.
The report has also provided a comprehensive analysis of the competitive landscape in the global cardiac PoC testing devices market. Detailed profiles of all major companies have been provided. Some of the companies covered include Abbott Laboratories, ACON Laboratories Inc., Alfa Scientific Designs Inc., Bio-Rad Laboratories Inc., Danaher Corporation, F. Hoffmann-La Roche AG, LifeSign LLC, Nano-Ditech Corporation, Nexus-Dx Inc., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.